Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-122-6 | CAS number: 5285-60-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In an acute oral toxicity test performed according to OECD guideline 423 and GLP principles, the oral LD50 of 4,4’-methylenebis-N-sec-butylaniline was found to be > 300 mg/kg bodyweight and < 2000 mg/kg bodyweight. An acute dermal study was performed according to OECD guideline 402 and GLP principles, the dermal LD50 value of 4,4’-methylenebis-N-sec-butylaniline in Wistar rats was determined to exceed 2000 mg/kg bodyweight. Both studies have Klimisch reliability 1.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 February 2018 - 20 March 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- December 2001
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- May 2008
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Version / remarks:
- December 2002
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Ministry of Agriculture, Forestry and Fisheries (JMAFF), 12 Nousan, Notification No 8147, November 2000, including the most recent partial revisions.
- Version / remarks:
- November 2000
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- no
- Specific details on test material used for the study:
- Adjustment was made for specific gravity of the test item.
Specific density: 0.99 g/cm3 - Species:
- rat
- Strain:
- other: Crl:WI (Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- - Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: Young adult animals (approx. 8-10 weeks old)
- Weight at study initiation: 139 to 187 g.
- Fasting period before study: yes
- Housing: Group housing of 3 animals per cage in labeled polycarbonate Macrolon cages containing sterilized sawdust as bedding material. For psychological/environmental enrichment, animals were provided with paper (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd).
- Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
- Water: Free access to tap water.
- Acclimation period: At least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 – 21
- Humidity (%): 26 - 51%
- Air changes (per hr): ten or more
- Photoperiod (hrs dark / hrs light): 12/12
Deviations from the minimum level of daily mean target humidity occurred (lowest value 26%). This study plan deviation is considered not to have affected the integrity of the study because it did not noticeably affect the clinical condition of the animals or the outcome of the study.
IN-LIFE DATES: From: 13 february 2018 to 20 March 2018 - Route of administration:
- oral: gavage
- Details on oral exposure:
- GAVAGE METHOD: syringe with a plastic gavage cannula
Frequency: single dosage, on day 1.
MAXIMUM DOSE VOLUME APPLIED:
2000 mg/kg body weight.
- Rationale for the selection of the starting dose: maximum recommended dose according to OECD 423. - Doses:
- 2000 mg/kg body weight
300 mg/kg body weight - No. of animals per sex per dose:
- 2000 mg/kg: 6 (2 groups of three females in a stepwise manner)
300 mg/kg: 6 (2 groups of three females) - Control animals:
- no
- Details on study design:
- The toxicity of the test item was assessed by stepwise treatment of groups of 3 females. The absence or presence of mortality of animals dosed at one step determined the next step, based on the test procedure defined in the guidelines. The onset, duration and severity of the signs of toxicity were taken into account for determination of the time interval between the dose groups. The first group was treated at a dose level of 2000 mg/kg. Based on the results, three additional groups were dosed at 2000, 300 and 300 mg/kg.
Animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test substance. Water was available ad libitum.
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Postdose observations were performed at periodic intervals on the day of dosing (at least three times) and once daily thereafter.
Mortality/Viability: Throughout the study, animals were observed for general health/mortality and moribundity twice daily, in the morning and at the end of the working day.
Body weights: Animals were weighed individually on day 1 (predose), 8 and 15.
Clinical signs: At periodic intervals on the day of dosing (day 1) and once daily thereafter, until Day 15.
- Necropsy of survivors performed: All moribund animals and animals surviving to the end of the observation period were sacrificed by oxygen/carbon dioxide procedure. All animals assigned to the study were subjected to necropsy and descriptions of all internal macroscopic abnormalities were recorded.
- Other examinations performed: none. - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- At 2000 mg/kg, all animals were sacrificed for humane reasons between days 8 and 11.
At 300 mg/kg, no mortality occurred. - Clinical signs:
- other: At 2000 mg/kg, in the first dose group, hunched posture and piloerection were noted on day 1 and ventro-lateral recumbency, hunched posture, decreased locomotor activity, piloerection, lean appearance and/or ptosis were noted from day 5 onwards. At 2000 m
- Gross pathology:
- At 2000 mg/kg, abnormalities of the thymus (reduced in size), liver (discolouration, pale) and stomach (irregular surface of the forestomach) and general emaciation were found for the animals that were sacrificed for humane reasons during the study, at macroscopic examination.
At 300 mg/kg abnormalities of the thymus (many tan foci) were noted for one animal. Macroscopic post mortem examination of the other animals did not reveal any abnormalities. - Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- In an acute oral toxicity test, the oral LD50 of 4,4’-methylenebis-N-sec-butylaniline was found to be > 300 mg/kg bodyweight and < 2000 mg/kg bodyweight.
- Executive summary:
An acute oral toxicity test was performed according to OECD guideline 423 and GLP principles. Three female Wistar rats were exposed to 2000 mg/kg body weight 4,4’-methylenebis-N-sec-butylaniline. In a stepwise procedure three additional groups of three females were dosed at 2000, 300 and 300 mg/kg body weight. At 2000 mg/kg, in the first dose group, hunched posture and piloerection were noted on day 1 and ventro-lateral recumbency, hunched posture, decreased locomotor activity, piloerection, lean appearance and/or ptosis were noted from day 5 onwards. At 2000 mg/kg, in the second dose group, hunched posture, uncoordinated movements, decreased locomotor activity and/or piloerection were noted from day 1 onwards. At 300 mg/kg, hunched posture, uncoordinated movements and/or piloerection were noted for the animals between days 1 and 2. In addition, quick breathing and chromodacryorrhoea (nose) were noted for one animal on day 1. At 2000 mg/kg, all animals were sacrificed for humane reasons between days 8 and 11. At 300 mg/kg, no mortality occurred. No abnormalities in weight were observed in all dose groups. Necroscopy performed on 2000 mg/kg dose groups showed abnormalities at the thymus (reduced in size), liver (discolouration, pale) and stomach (irregular surface of the forestomach) and general emaciation were found for the animals that were sacrificed for humane reasons during the study, at macroscopic examination. At 300 mg/kg, abnormalities of the thymus (many tan foci) were noted for one animal. Macroscopic post mortem examination of the other animals did not reveal any abnormalities.
Based on these results, the oral LD50 of 4,4’-methylenebis-N-sec-butylaniline was found to be > 300 mg/kg bodyweight and therefore according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2017) (including all amendments) and according to the Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments), 4,4’-methylenebis-N-sec-butylaniline should be classified as Category 4 and should be labeled as H302: Harmful if swallowed.
Reference
According to the OECD 423 test guideline, the LD50 cut-off value was considered to be 500 mg/kg body weight.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 300 mg/kg bw
- Quality of whole database:
- The study was performed according to OECD/EC guidelines and GLP principles.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 March 2018 - 23 April 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- 2017
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Specific details on test material used for the study:
- Adjustment was made for specific gravity of the test item.
- Species:
- rat
- Strain:
- other: Crl: WI(Han)
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Females nulliparous and non-pregnant:yes
- Age at study initiation: approx. 10 - 12 weeks old
- Weight at study initiation: Females: 191 - 226 g.
- Housing: During the acclimatization period the animals were group housed in Makrolon cages (MIV type, height 18 cm) containing sterilized sawdust as bedding material and paper as cage-enrichment. During the study the animals were individually housed in Makrolon cages (MIII type, height 18 cm.).
- Diet: Pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 5 days
IN-LIFE DATES: From: 26 March 2018 To: 23 April 2018
Periodic analysis of the water was performed and feed was analyzed by the supplier for nutritional components and environmental contaminants.
It is considered that there were no known contaminants in the feed or water that would interfere with the objectives of the study.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 21
- Humidity (%): 43 - 51
- Air changes (per hr): >= 10
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- Area of exposure: 18 cm^2
- % coverage: approx. 10% of the total body surface
- Type of wrap if used: a surgical gauze patch (Surgy 1D), successively covered with Coban elastic bandage. A piece of Micropore tape was additionally used for fixation of the bandages
REMOVAL OF TEST SUBSTANCE
- Washing: tap water
- Time after start of exposure: 24 hours
- Duration of exposure:
- 24 hours
- Doses:
- 2000 mg/kg bodyweight
- No. of animals per sex per dose:
- Main study: 2 females at 2000 mg/kg bodyweight
Range finding study: 1 female at 1000 mg/kg bodyweight and 1 female at 2000 mg/kg bodyweight - Control animals:
- not required
- Details on study design:
- RANGEFINDING STUDY:
A range finding study was performed in order to select the dose causing no mortality or significant toxicity to be used in the main study. Initially, one animal was dosed at 1000 mg/kg bodyweight. A period of at least 48 hours was allowed between the dosing of each animal. Based on the results one additional animal was dosed at 2000 mg/kg.
MAIN STUDY:
- Duration of observation period following administration: 14 days
- Frequency of observations:
- Mortality: twice daily
- Clinical observations: at periodic intervals on the day of dosing and once daily thereafter.
- Body weights: on day 1 (pre-administration), day 8 and day 15.
- Irritation: The skin reactions were assessed approximately 24, 48 and 72 hours after the removal of the dressing and test item. Adjacent areas of untreated skin of each animal served as controls.
- Necropsy of survivors performed: yes - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred.
- Clinical signs:
- other: No clinical signs were noted in any of the animals.
- Gross pathology:
- No abnormalities were seen at necropsy.
- Other findings:
- Irritation effects: General erythema of the right flank was noted for one animal on day 4.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on the results of an acute dermal study, performed according to OECD guideline 402 and GLP principles, the dermal LD50 value of 4,4’-methylenebis-N-sec-butylaniline in Wistar rats was determined to exceed 2000 mg/kg bodyweight. As a consequence, 4,4’-methylenebis-N-sec-butylaniline is not classified according to CLP criteria.
- Executive summary:
An acute dermal study was performed according to OECD guideline 402 and GLP principles. two female rats were exposed at test item concentration of 2000 mg/kg bodyweight and observed for 14 days. No mortality occurred. General erythema of the right flank was noted for one animal on day 4 only. No unexpected changes in body weight gain occurred, no clinical signs were observed and no abnormalities were seen at necropsy. These results demonstrate that the dermal LD50 value of 4,4’-methylenebis-N-sec-butylaniline in Wistar rats exceeds 2000 mg/kg body weight. As a consequence, 4,4’-methylenebis-N-sec-butylaniline is not classified according to Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The study was performed according to OECD/EC guidelines and GLP principles.
Additional information
An acute oral toxicity test was performed according to OECD guideline 423 and GLP principles. Three female Wistar rats were exposed to 2000 mg/kg body weight 4,4’-methylenebis-N-sec-butylaniline. In a stepwise procedure three additional groups of three females were dosed at 2000, 300 and 300 mg/kg body weight. At 2000 mg/kg, in the first dose group, hunched posture and piloerection were noted on day 1 and ventro-lateral recumbency, hunched posture, decreased locomotor activity, piloerection, lean appearance and/or ptosis were noted from day 5 onwards. At 2000 mg/kg, in the second dose group, hunched posture, uncoordinated movements, decreased locomotor activity and/or piloerection were noted from day 1 onwards. At 300 mg/kg, hunched posture, uncoordinated movements and/or piloerection were noted for the animals between days 1 and 2. In addition, quick breathing and chromodacryorrhoea (nose) were noted for one animal on day 1. At 2000 mg/kg, all animals were sacrificed for humane reasons between days 8 and 11. At 300 mg/kg, no mortality occurred. No abnormalities in weight were observed in all dose groups. Necroscopy performed on 2000 mg/kg dose groups showed abnormalities at the thymus (reduced in size), liver (discolouration, pale) and stomach (irregular surface of the forestomach) and general emaciation were found for the animals that were sacrificed for humane reasons during the study, at macroscopic examination. At 300 mg/kg, abnormalities of the thymus (many tan foci) were noted for one animal. Macroscopic post mortem examination of the other animals did not reveal any abnormalities. Based on these results, the oral LD50 of 4,4’-methylenebis-N-sec-butylaniline was found to be > 300 mg/kg bodyweight.
An acute dermal study was performed according to OECD guideline 402 and GLP principles. A range finding study was performed in order to select the dose causing no mortality or significant toxicity to be used in the main study. In the main study, two female rats were exposed at test item concentration of 2000 mg/kg bodyweight and observed for 14 days. No mortality occurred. General erythema of the right flank was noted for one animal on day 4 only. No unexpected changes in body weight gain occurred, no clinical signs were observed and no abnormalities were seen at necropsy. These results demonstrate that the dermal LD50 value of 4,4’-methylenebis-N-sec-butylaniline in Wistar rats exceeds 2000 mg/kg body weight.
Justification for classification or non-classification
Based on these results, the oral LD50 of 4,4’-methylenebis-N-sec-butylaniline was found to be > 300 mg/kg bodyweight and therefore according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2017) (including all amendments) and according to the Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments), 4,4’-methylenebis-N-sec-butylaniline is classified for oral toxicity in Category 4 and should be labeled as H302: Harmful if swallowed.
The dermal LD50 of 4,4’-methylenebis-N-sec-butylaniline was found to be > 2000 mg/kg bodyweight, therefore 4,4’-methylenebis-N-sec-butylaniline is not classified for dermal toxicity according to Regulation (EC) No 1272/2008 on classification, labelling and packaging of items and mixtures (including all amendments).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.